US SB607 | 2023-2024 | 118th Congress
Status
Spectrum: Slight Partisan Bill (Democrat 2-1)
Status: Introduced on March 1 2023 - 25% progression, died in committee
Action: 2023-03-01 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Pending: Senate Health, Education, Labor, And Pensions Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on March 1 2023 - 25% progression, died in committee
Action: 2023-03-01 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Pending: Senate Health, Education, Labor, And Pensions Committee
Text: Latest bill text (Introduced) [PDF]
Summary
A bill to allow the Secretary of Health and Human Services to deny approval of a new drug application for an opioid analgesic drug on the basis of such drug not being clinically superior to other commercially available drugs.
Title
EFFECTIVE Act Ensuring the FDA Fully Examines Clinical Trial Impact and Vitalness before Endorsement Act
Sponsors
| Sen. Joe Manchin [D-WV] | Sen. Mike Braun [R-IN] | Sen. Tammy Baldwin [D-WI] |
History
| Date | Chamber | Action |
|---|---|---|
| 2023-03-01 | Senate | Read twice and referred to the Committee on Health, Education, Labor, and Pensions. |
Same As/Similar To
HB1375 (Same As) 2023-03-10 - Referred to the Subcommittee on Health.
Subjects
US Congress State Sources
| Type | Source |
|---|---|
| Summary | https://www.congress.gov/bill/118th-congress/senate-bill/607/all-info |
| Text | https://www.congress.gov/118/bills/s607/BILLS-118s607is.pdf |
